Results 21 to 30 of about 53,372 (96)

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

open access: yesJournal of Clinical Oncology, 2004
PURPOSE To evaluate the efficacy, safety, and pharmacokinetics of multiple doses of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma (RCC). PATIENTS AND METHODS Patients (n = 111)
M. Atkins   +11 more
semanticscholar   +1 more source

The Rapalogue, CCI-779, Improves Salivary Gland Function following Radiation

open access: yesPLoS ONE, 2014
The standard of care for head and neck cancer typically includes surgical resection of the tumor followed by targeted head and neck radiation. However depending on tumor location and stage, some cases may not require surgical resection while others may ...
M. Morgan-Bathke   +6 more
semanticscholar   +1 more source

Potential role of polycyclic aromatic hydrocarbons in air pollution-induced non-malignant respiratory diseases

open access: yesRespiratory Research, 2020
Epidemiological studies have found strong associations between air pollution and respiratory effects including development and/or exacerbation of asthma and chronic obstructive pulmonary disease (COPD) as well as increased occurrence of respiratory ...
Marit Låg   +3 more
doaj   +1 more source

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

open access: yesJournal of Clinical Oncology, 2005
BACKGROUND Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM).
E. Galanis   +14 more
semanticscholar   +1 more source

The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells

open access: yesCancer Cell International, 2013
BackgroundLiver cancer is one of the most frequent cancers in the world. Targeted therapy of cancer with specific inhibitors is developing and has shown promising antitumor efficacy.
Shu-yu Li   +6 more
semanticscholar   +1 more source

Phosphorylation of Serine 779 in Fibroblast Growth Factor Receptor 1 and 2 by Protein Kinase Cϵ Regulates Ras/Mitogen-activated Protein Kinase Signaling and Neuronal Differentiation*

open access: yesJournal of Biological Chemistry, 2013
Background: The FGF receptors (FGFRs) regulate pleiotropic (diverse) cellular responses. Results: Serine 779 phosphorylation of FGFR1 and 2 by PKCϵ promotes maximal Ras/MAPK signaling and neuronal differentiation.
A. Lonic   +7 more
semanticscholar   +1 more source

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

open access: yesScience, 2020
The COVID-19 RNA-synthesizing machine Many in the scientific community have mobilized to understand the virus that is causing the global coronavirus disease 2019 (COVID-19) pandemic. Gao et al.
Yan Gao   +27 more
semanticscholar   +1 more source

Atopy is a risk factor for adult asthma in urban community of Southwestern Nigeria

open access: yesLung India, 2012
Rationale: Factors affecting asthma course are not clearly elucidated in urban communities in developing countries. Furthermore, the interaction between factors such as atopy, environmental exposure, urbanization, and helminthic infections in modulating ...
O M Ige, A G Falade, O G Arinola
doaj   +1 more source

Superior vena caval syndrome and ipsilateral pleural effusion: A rare presentation of anterior mediastinal thymoma

open access: yesLung India, 2014
Incidence of thymic malignancies is very low. Thymoma, a tumor of thymus gland, is of epithelial origin and is most common anterior mediastinal tumor. In most cases, thymomas are localized and locally advanced thymomas may rarely present with superior ...
Anirban Das   +4 more
doaj   +1 more source

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

open access: yesJournal of Clinical Oncology, 2004
PURPOSE To establish the safety, tolerability, and pharmacokinetic parameters of CCI-779, a selective inhibitor of the mammalian target of rapamycin, in patients with advanced cancer. PATIENTS AND METHODS Using a modified continuous reassessment method,
E. Raymond   +9 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy